Compounded Semaglutide - Safety Information

Overview
Compounded semaglutide is an injectable medication used to support weight management in adults who are obese or overweight with related medical conditions. Acting as a GLP-1 receptor agonist, it helps regulate blood sugar levels and reduce appetite. Note: compounded semaglutide is not FDA-approved, and its safety, efficacy, and manufacturing standards are not evaluated like FDA-approved medications.

Indications for Use

Obesity: BMI ≥ 30 kg/m²

Overweight: BMI ≥ 27 kg/m² with at least one weight-related condition (e.g., type 2 diabetes, hypertension, dyslipidemia)

Important Safety Information

Warning – Thyroid C-Cell Tumors:
Animal studies showed semaglutide may cause thyroid tumors. Use is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

Watch for symptoms:

Neck lump or swelling

Hoarseness or trouble swallowing

Shortness of breath

Contraindications:
Do not use if you:

Have a history of MTC or MEN 2

Are allergic to semaglutide or any ingredients

Are pregnant or planning pregnancy

Common Side Effects:

Nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion

Injection site reactions (redness, pain, swelling)

Fatigue and dizziness

Increased heart rate

Serious Side Effects:

Acute pancreatitis (severe abdominal pain)

Acute kidney injury (from dehydration)

Gallbladder disease (pain, jaundice, clay-colored stools)

Worsening diabetic retinopathy

Severe hypoglycemia (especially with other glucose-lowering medications)

Serious allergic reactions

Drug Interactions:

Diabetes medications: Increased risk of hypoglycemia

Oral medications: Absorption may be delayed due to slowed gastric emptying

Usage Guidelines:

Administer subcutaneously once weekly (abdomen, thigh, upper arm)

Missed dose: Take within 5 days; otherwise, skip and resume normal schedule

Special Precautions:

Monitor kidney function, especially if a history of kidney disease exists

Watch for mood changes, depression, or suicidal thoughts

Monitoring:

Regular monitoring of blood glucose, kidney function, and mental health is recommended

Report new or worsening symptoms immediately

FDA Approval Note:
Compounded semaglutide is not FDA-approved. Use under a healthcare provider’s supervision and fully understand potential risks and benefits.

Disclaimer:
Consult your healthcare provider to ensure this information applies to you. Report adverse reactions or concerns promptly.